Cytosorbents Financial Statements From 2010 to 2025

CTSO Stock  USD 0.94  0.01  0.61%   
Cytosorbents Crp's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Cytosorbents Crp's valuation are provided below:
Gross Profit
24.8 M
Profit Margin
(0.27)
Market Capitalization
58.1 M
Enterprise Value Revenue
2.0895
Revenue
36.1 M
We have found one hundred twenty available fundamental signals for Cytosorbents Crp, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Cytosorbents Crp's prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 30th of September 2025, Market Cap is likely to grow to about 98.6 M. Also, Enterprise Value is likely to grow to about 92.1 M

Cytosorbents Crp Total Revenue

37.37 Million

Check Cytosorbents Crp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytosorbents Crp's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 797 K or Selling General Administrative of 36.7 M, as well as many indicators such as Price To Sales Ratio of 1.32, Dividend Yield of 0.002 or PTB Ratio of 4.68. Cytosorbents financial statements analysis is a perfect complement when working with Cytosorbents Crp Valuation or Volatility modules.
  
Build AI portfolio with Cytosorbents Stock
Check out the analysis of Cytosorbents Crp Correlation against competitors.
To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.

Cytosorbents Crp Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets25 M47.4 M30.7 M
Slightly volatile
Short and Long Term Debt Total28.2 M26.9 M10 M
Slightly volatile
Total Current Liabilities5.6 M9.8 M6.7 M
Slightly volatile
Cash3.1 M3.3 M14.8 M
Slightly volatile
Common Stock Total Equity51.6 K39.3 K67.9 K
Slightly volatile
Common Stock Shares Outstanding57.2 M54.4 M28.8 M
Slightly volatile
Liabilities And Stockholders Equity25.1 M47.4 M30.7 M
Slightly volatile
Total Liabilities38.1 M36.3 M17.2 M
Slightly volatile
Property Plant And Equipment Gross26 M24.7 M8.1 M
Slightly volatile
Total Current Assets17.8 M21.6 M21.8 M
Slightly volatile
Other Current Liabilities2.8 M5.2 M3.3 M
Slightly volatile
Property Plant And Equipment Net21.5 M20.5 M7.3 M
Slightly volatile
Non Current Assets Total27.1 M25.8 M10.2 M
Slightly volatile
Cash And Short Term Investments3.1 M3.3 M15.1 M
Slightly volatile
Non Current Liabilities Total27.8 M26.4 M10.3 M
Slightly volatile
Other Stockholder Equity168.9 M310.8 M178.6 M
Slightly volatile
Common Stock53 K54.8 K69.6 K
Slightly volatile
Accounts Payable3.5 M3.3 M1.8 M
Slightly volatile
Non Currrent Assets Other21.5 K22.6 K1.1 M
Pretty Stable
Other Current Assets8.7 M8.3 M2.1 M
Slightly volatile
Good Will5.1 M4.9 M2.4 M
Slightly volatile
Intangible AssetsM3.7 M2.1 M
Slightly volatile
Other Assets1.1 MM1.2 M
Slightly volatile
Property Plant Equipment13 M12.4 M4.8 M
Slightly volatile
Net Receivables7.7 M7.3 M3.2 M
Slightly volatile
Inventory1.9 M2.7 M1.7 M
Slightly volatile
Short Term Debt1.4 M905.4 K1.3 M
Pretty Stable
Net Tangible Assets23.3 M40.7 M19.6 M
Slightly volatile
Current Deferred Revenue398.4 K419.3 K619.5 K
Slightly volatile
Capital Surpluse215.6 M330.1 M188.2 M
Slightly volatile
Short and Long Term Debt1.8 M2.9 M1.7 M
Slightly volatile
Long Term Debt TotalM15.4 M8.4 M
Slightly volatile
Long Term Investments133.2 K144.8 K118.2 K
Slightly volatile
Net Invested Capital41.4 M25.1 M30.3 M
Slightly volatile
Net Working Capital21.5 M11.8 M20.5 M
Slightly volatile
Capital Stock47.7 K54.8 K37.9 K
Slightly volatile
Capital Lease Obligations10.1 M12.9 M4.7 M
Slightly volatile

Cytosorbents Crp Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.8 M1.7 M638.7 K
Slightly volatile
Selling General Administrative36.7 M35 M19.6 M
Slightly volatile
Total Revenue37.4 M35.6 M17.9 M
Slightly volatile
Other Operating Expenses55 M52.4 M31.4 M
Slightly volatile
Cost Of RevenueM10.5 M5.8 M
Slightly volatile
Total Operating Expenses44 M41.9 M25.3 M
Slightly volatile
Selling And Marketing Expenses380.3 K391.5 K401.7 K
Very volatile
Research Development6.6 M6.9 MM
Slightly volatile
Preferred Stock And Other Adjustments287.1 K302.2 K845.5 K
Slightly volatile
Non Recurring1.2 M1.5 M1.2 M
Slightly volatile
Interest Income113.7 K119.7 K509.6 K
Pretty Stable
Reconciled Depreciation1.1 M1.7 M655.9 K
Slightly volatile

Cytosorbents Crp Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow12.8 M15.6 M15.6 M
Slightly volatile
Depreciation1.8 M1.8 M639.7 K
Slightly volatile
Total Cash From Financing Activities10.1 M9.3 M11.9 M
Pretty Stable
End Period Cash Flow13.3 M9.8 M16.2 M
Slightly volatile
Stock Based Compensation3.2 M3.8 M2.6 M
Slightly volatile
Change To Netincome4.3 M8.1 M3.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.321.3917214
Slightly volatile
Dividend Yield0.0020.00220.0105
Slightly volatile
Days Sales Outstanding88.9775.05886.8635
Slightly volatile
Average Payables3.7 M3.6 M1.8 M
Slightly volatile
Stock Based Compensation To Revenue0.20.10560.2066
Slightly volatile
Capex To Depreciation0.150.16242.9657
Very volatile
EV To Sales1.952.0551213
Slightly volatile
Inventory Turnover3.163.83053.6537
Pretty Stable
Days Of Inventory On Hand90.5295.28661.8 K
Slightly volatile
Payables Turnover2.813.13443.2469
Slightly volatile
Sales General And Administrative To Revenue1.331.47.5302
Slightly volatile
Average Inventory3.2 M3.1 M1.9 M
Slightly volatile
Research And Ddevelopement To Revenue0.180.194311.5302
Slightly volatile
Capex To Revenue0.00760.0080.2787
Slightly volatile
Cash Per Share0.05720.06030.455
Pretty Stable
Days Payables Outstanding1111162.8 K
Slightly volatile
Income Quality0.60.69640.7443
Pretty Stable
Intangibles To Total Assets0.10.07910.0922
Slightly volatile
Current Ratio1.952.1992.5827
Slightly volatile
Receivables Turnover4.224.86294.9138
Slightly volatile
Capex Per Share0.0050.00520.041
Pretty Stable
Average ReceivablesM6.7 M3.1 M
Slightly volatile
Revenue Per Share0.350.65390.4383
Slightly volatile
Interest Debt Per Share0.330.51970.2767
Slightly volatile
Debt To Assets0.60.56770.3601
Slightly volatile
Operating Cycle1621701.9 K
Slightly volatile
Days Of Payables Outstanding1111162.8 K
Slightly volatile
Ebt Per Ebit0.741.3351.1623
Slightly volatile
Effective Tax Rate0.06720.07550.0614
Slightly volatile
Quick Ratio1.821.92082.3704
Slightly volatile
Net Income Per E B T0.660.92450.9216
Pretty Stable
Cash Ratio0.320.33391.7186
Pretty Stable
Days Of Inventory Outstanding90.5295.28661.8 K
Slightly volatile
Days Of Sales Outstanding88.9775.05886.8635
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.881.01971.0994
Pretty Stable
Fixed Asset Turnover1.651.73525.7201
Very volatile
Debt Ratio0.60.56770.3601
Slightly volatile
Price Sales Ratio1.321.3917214
Slightly volatile
Asset Turnover0.790.75140.4788
Slightly volatile

Cytosorbents Crp Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap98.6 M49.5 M115.6 M
Pretty Stable
Enterprise Value92.1 M73.1 M108 M
Pretty Stable

Cytosorbents Fundamental Market Drivers

Forward Price Earnings7.734
Cash And Short Term Investments3.3 M

Cytosorbents Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cytosorbents Crp Financial Statements

Cytosorbents Crp investors utilize fundamental indicators, such as revenue or net income, to predict how Cytosorbents Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue419.3 K398.4 K
Total Revenue35.6 M37.4 M
Cost Of Revenue10.5 MM
Stock Based Compensation To Revenue 0.11  0.20 
Sales General And Administrative To Revenue 1.40  1.33 
Research And Ddevelopement To Revenue 0.19  0.18 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.65  0.35 
Ebit Per Revenue(0.47)(0.50)

Pair Trading with Cytosorbents Crp

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytosorbents Crp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytosorbents Crp will appreciate offsetting losses from the drop in the long position's value.

Moving against Cytosorbents Stock

  0.4EKSO Ekso Bionics HoldingsPairCorr
  0.38LH LaboratoryPairCorr
  0.37EMBC Embecta CorpPairCorr
The ability to find closely correlated positions to Cytosorbents Crp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytosorbents Crp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytosorbents Crp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytosorbents Crp to buy it.
The correlation of Cytosorbents Crp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytosorbents Crp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytosorbents Crp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytosorbents Crp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Cytosorbents Crp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytosorbents Crp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytosorbents Crp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytosorbents Crp Stock:
Check out the analysis of Cytosorbents Crp Correlation against competitors.
To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytosorbents Crp. If investors know Cytosorbents will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytosorbents Crp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.18)
Revenue Per Share
0.621
Quarterly Revenue Growth
0.088
Return On Assets
(0.20)
Return On Equity
(0.70)
The market value of Cytosorbents Crp is measured differently than its book value, which is the value of Cytosorbents that is recorded on the company's balance sheet. Investors also form their own opinion of Cytosorbents Crp's value that differs from its market value or its book value, called intrinsic value, which is Cytosorbents Crp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytosorbents Crp's market value can be influenced by many factors that don't directly affect Cytosorbents Crp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytosorbents Crp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytosorbents Crp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytosorbents Crp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.